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Abstract
Background: Traditional determinants proven to be of prognostic importance in breast cancer include the TNM
staging, histological grade, proliferative activity, hormone receptor status and HER2 overexpression. One of the
limitations of the histological grading scheme is that a high percentage of breast cancers are still classified as
grade 2, a category with ambiguous clinical significance. The aim of this study was to best characterize tumors
scored as grade 2.
Methods: We investigated traditional prognostic factors and a panel of tumor markers not used in routine diagnosis,
such as NHERF1, VEGFR1, HIF-1a and TWIST1, in 187 primary invasive breast cancers by immunohistochemistry,
stratifying patients into good and poor prognostic groups by the Nottingham Prognostic Index.
Results: Grade 2 subgroup analysis showed that the PVI (p = 0.023) and the loss of membranous NHERF1 (p =
0.028) were adverse prognostic factors. Relevantly, 72% of grade 2 tumors were associated to PVI+/membranous
NHERF1- expression phenotype, characterizing an adverse prognosis (p = 0.000). Multivariate logistic regression
analysis in the whole series revealed poor prognosis correlated with PVI and MIB1 (p = 0.000 and p = 0.001,
respectively). Furthermore, in the whole series of breast cancers we found cytoplasmic NHERF1 expression
positively correlated to VEGFR1 (r = 0.382, p = 0.000), and in VEGFR1-overexpressing tumors the oncogenic
receptor co-localized with NHERF1 at cytoplasmic level.
Conclusions: The PVI+/membranous NHERF1- expression phenotype identifies a category of grade 2 tumors with
the worst prognosis, including patient subgroup with a family history of breast cancer. These observations support
the idea of the PVI+/membranous NHERF1- expression immunophenotype as a useful marker, which could
improve the accuracy of predicting clinical outcome in grade 2 tumors.
Keywords: NHERF1, Peritumoral Vascular Invasion, Histological grade, Breast cancer, VEGFR1, Nottingham Prognos-
tic Index
Background
Breast cancer represents a heterogeneous disease with
an intrinsic complexity in cellular-biomolecular profile
and in its responsiveness to treatment [1]. The manage-
ment of early-stage breast cancer is based on clinical
and pathological parameters which are able to predict
distinct patient outcomes. Traditional determinants pro-
ven to be of prognostic importance and used in routine
practice include the pathological subtype, TNM staging
information, histological grade, proliferative activity,
receptor status and human epidermal growth factor
receptor 2 (HER2) overexpression.
T h ed e g r e eo fh i s t o l o g i c a ld ifferentiation in operable
breast carcinomas has long represented one of the best
established prognostic factors which have been validated
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Ellis modification of the Scarff-Bloom-Richardson grad-
ing system separates breast cancer patients into distinct
prognosis groups: grade 1, 2 or 3, with a low, intermedi-
ate or high risk of recurrence, respectively [5]. Although
internationally accepted among pathologists, one of the
limitations of the histological grading scheme is that a
high percentage (30% to 60%) of breast cancer is still
classified as grade 2, a category with ambiguous clinical
significance [6].
To be of clinical use, a prognostic factor must show a
wide separation in the outcome of the groups identified
and select adequate numbers in each group [7]. Not-
withstanding many efforts, no single prognostic factor
in breast cancer meets these criteria. Histological grad-
ing has been combined with tumor size and lymph
node stage to form the Nottingham Prognostic Index
(NPI), which allows stratification of patients into three
different prognostic groups [3] and satisfying these
criteria.
Within the last decade, several attempts have been per-
formed to classify grade 2 tumors into two distinct mole-
cular subclasses, improving biological and clinical
usefulness of histological grading [8-15]. A multitude of
factors, such as HER2, p53, proliferation markers and
vascular channel invasion, has been extensively studied
and tested in clinical settings, but their importance needs
to be validated in statistically robust studies.
Over the last years, laboratory research has proposed
novel prognostic markers but not sufficiently investigated
to demonstrate their prognostic value. Most of these
markers are involved in breast cancer biology and related
to essential aspects of cell life, proliferation, transforma-
tion and apoptosis [16]. Recently, we have demonstrated
that the Na
+⁄H
+ exchanger regulatory factor 1 (NHERF1),
an adaptor protein for membrane macromolecular com-
plexes, is a potential candidate of clinical relevance for
human breast cancer [17-19]. The strong correlation
with poor vascularization and the hypoxia-inducible fac-
tor-1a (HIF-1a), a marker of hypoxic tumors, indicates
that NHERF1 expression might play an important role in
driving metastatic progression by modifying the tumor
microenvironment [20]. Among several hypoxia related
genes, the vascular endothelial growth factor (VEGF)
mediates its effects on proliferation and survival mostly
through the VEGF receptor 1 (VEGFR1) and 2 (VEGFR2)
within endothelial cells. Nevertheless, it has been demon-
strated that VEGFR1 expression in breast cancer cells
correlated significantly with high metastasis risk and
relapse [21,22]. During malignant cancer progression,
TWIST1 plays a role in the development of distant
metastasis by inducing an epithelial-to-mesenchymal
transition of epithelial breast cancer cells and by prompt-
ing them to enter the bloodstream [23,24].
In this study we examined traditional prognostic factors
and a panel of protein markers associated with breast can-
cer progression, aggressiveness, hypoxic response and cell
invasion/metastasis, respectively NHERF1, VEGFR1, HIF-
1a and TWIST1, to determine whether they are differen-
tially expressed in tumors scored as grade 2, trying to
improve their prognosis definition.
Methods
Patients and tumor specimens
A selected series of 187 primary invasive breast carcino-
mas were included in this study: 48% (n = 90) were
sporadic patients and 52% (n = 97) were classified as
having a family history, after a genetic counseling pro-
gram as reported previously [25]. None of the sporadic
patients had a family history of breast or ovarian cancer.
Table 1 lists the patients’ clinicopathological features.
All histological sections of tumor specimens were re-
evaluated by two experienced pathologists, performed
without any knowledge of patient history. Each patient
was staged according to the International Union Against
Cancer TNM classification [26]. The tumor size was ≤ 2
cm in 41% (n = 77) of cases and > 2 cm in 59% (n =
110) of cases. Pathological examination revealed that
axillary lymph node status was positive in 59% (n = 101)
and negative in 41% (n = 71) of patients. Histological
grading was performed according to the Elston and Ellis
method [2] and 17% (n = 31) of tumors were histologi-
cal grade 1, 46% (n = 87) were grade 2 and 37% (n =
69) were grade 3. Moreover, within the familial cancer
group, 49% (48/97) were grade 2. Of all tumors, 150
(80%) cases were invasive ductal carcinoma (IDC) not
otherwise specified (NOS), with the remainder 37 (20%)
consisting of other histological types including medul-
lary, tubular, atypical medullary and lobular tumors.
Assessment of the peritumoral vascular invasion (PVI)
was based upon examination of sections stained with
haematoxylin and eosin and was considered evident if at
least one cohesive clump of tumor cells was clearly visi-
ble within peritumoral endothelial-lined spaces, both
lymphatic channels and small blood vessels–closely
associated with primary invasive carcinoma [27].
The NPI was calculated according to the following
equation: NPI = tumor size (cm) × 0.2 + tumor grade (1-
3) + lymph node stage (A-C). Stage A, stage B and stage
C denoted lesions with 0, with ≤ 3 and with > 3 involved
lymph nodes, respectively [28]. Thus, on the basis of
obtained NPI, each patient was assigned to one of three
prognostic groups: Good (NPI ≤ 3.4), Moderate (3.4 <
NPI ≤ 5.4) and Poor (NPI > 5.4). Then, we verified
whether breast cancers with Good, Moderate or Poor
prognosis were associated with a series of well-defined
biological factors and with tumor markers not currently
used in routine diagnosis.
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estrogen receptor (ER) and progesterone receptor (PR)
status, tumor proliferative activity (MIB1), HER2 status,
NHERF1, VEGFR1, HIF-1a and TWIST1.
Information regarding patient characteristics, including
age, tumor size, nodal status, tumor grade, histologic
tumor type, PVI, MIB1, ER, PR and HER2 status, was col-
lected from the Pathology Department of our Institute.
ER, PR and MIB1 immunostainings were confined to the
nucleus and were performed according to method pre-
viously explained [25]. ER and PR were regarded overex-
pressed when > 10% of nuclei were positive. Cases with a
MIB1 index > 20% were considered high proliferating
tumors. The MIB1 cut-off represents the median value of
the scores relative to all breast tumor samples analyzed
during the last five years within our Institute. The HER2
status was scored as 0, 1+, 2+ or 3+, using a monoclonal
antibody (MoAb clone CB11, Novocastra Laboratories
Ltd, Newcastle, UK), in accordance with the Herceptest
scoring system (Food and Drug Administration
accepted): 0, no membranous immunoreactivity or < 10%
of cells reactive; 1+, incomplete membranous reactivity
in > 10% of cells; 2+, > 10% of cells with weak to moder-
ate complete membranous reactivity; and 3+, strong and
complete membranous reactivity in > 10% of cells. Cyto-
plasmic immunoreactivity was ignored. Cases scored 0
and 1+ were classified as negative, and cases scored 3+
were classified as positive. Cases regarded as indetermi-
nate (2+) were tested for HER2 gene amplification by
fluorescence in situ hybridization (FISH), as previously
reported [17]. Briefly, using a dual probe system of differ-
ent colors (PathVysion HER-2 DNA probe kit, Vysis-
Olympus, Milan, Italy), the gene copy numbers of HER2
and centromeres of the corresponding chromosome 17
were retrieved. The FISH results were regarded as posi-
tive when the HER2/CEP17 ratio was ≥ 2.2. Cases with
ratio 1.8 and 2.1 were defined as borderline. A signal was
defined as significantly amplified if it was overrepresented
in approximately 20% of nuclei. The study was performed
with the approval of the Ethics Committee of our Insti-
tute. Each individual involved in the study signed an
informed consent form authorizing the Institute to utilize
their biological tissues for research purpose. All the ana-
lyses were performed in the ISO9001-2000 certified Clin-
ical Experimental Oncology Laboratory of the National
Cancer Centre of Bari (DNV Certificate No CERT-
17885-2006-AQ-BRI-SINCERT).
Table 1 Clinicopathological features and tumor marker
expressions in a cohort of 187 invasive breast cancer
patients
Parameter Total, n (%)
Age at diagnosis
Median (range) 50 years (24-83)
Tumor size
≤ 2 cm 77 (41)
> 2 cm 110 (59)
Nodal status
Negative 71 (41)
Positive 101 (59)
Tumor grade
1 31 (17)
2 87 (46)
3 69 (37)
Histologic tumor type
IDC (NOS) 150 (80)
Other histologic type 37 (20)
PVI
Absent 114 (66)
Present 59 (34)
NPI
Good (≤ 3.4) 49 (26)
Moderate (3.4-5.4) 88 (47)
Poor (> 5.4) 50 (27)
ER status
Negative (≤ 10%) 53 (29)
Positive (> 10%) 131 (71)
PR status
Negative (≤ 10%) 76 (42)
Positive (> 10%) 107 (58)
MIB1
Negative (≤ 20%) 79 (43)
Positive (> 20%) 104 (57)
HER2 status
Negative 133 (85)
Positive 23 (15)
Cytoplasmic NHERF1
Negative (≤ 40%) 105 (69)
Positive (> 40%) 47 (31)
Membranous NHERF1
Negative (0%) 134 (87)
Positive (> 0%) 20 (13)
VEGFR1
Negative (≤ 2%) 82 (50)
Positive (> 2%) 82 (50)
HIF-1a
Negative (0%) 98 (63)
Positive (> 0%) 58 (37)
TWIST1
Negative (≤ 3%) 69 (49)
Positive (> 3%) 73 (51)
Abbreviations: Tumor grade = histological differentiation grade;
IDC (NOS) invasive ductal carcinoma (not otherwise specified);
PVI = peritumoral vascular invasion;
NPI = Nottingham Prognostic Index;
ER = estrogen receptor; PR = progesterone receptor;
HER2 = human epidermal growth factor receptor 2
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Sections of 4 μm-thickness were immunohistochemically
stained using standard immunoperoxidase techniques.
Slides were deparaffinized and rehydrated through a graded
ethanol series. Endogenous peroxidase activity was blocked
by incubation in 0.3% H2O2 buffer solution. Epitope anti-
gen retrieval was carried out by boiling of slides in 0.01 M
sodium citrate buffer (pH 6.0). For NHERF1, sections were
incubated with a rabbit polyclonal EBP50 antibody (PA1-
090, 1:150 dilution; Affinity Bioreagents, Golden, CO,
USA). Immunohistochemical analysis of NHERF1 was
based on subcellular localization of the protein and classi-
fied as cytoplasmic and/or membranous for each sample,
as previously described [17]. According to median value
cut-off, cases were classified positive when cytoplasmic
NHERF1 immunoreactivity was present in > 40% of tumor
cells and when membranous NHERF1 expression was
detected in > 0% of tumor cells examined. HIF-1a staining
was performed with a rabbit polyclonal antibody (H206,
1:100 dilution; Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA). For HIF-1a only cells with completely and
darkly stained epithelial nuclei were regarded as positive.
HIF-1a was considered overexpressed when > 0% of nuclei
were positive and the typical expression pattern (perinecro-
tic or diffuse) was noted [29]. Cytoplasmic staining of HIF-
1a, observed occasionally, was ignored. The rabbit polyclo-
nal antibody anti-VEGFR1 (C-17, 1:100 dilution; Santa
Cruz Biotechnology Inc.), which recognizes the C-terminus
of the human receptor 1 for VEGF, was incubated for 1 h
at room temperature [30]. VEGFR1 was mainly observed
in the cytoplasm of breast cancer tissues, and the staining
was evaluated as percentage of immunoreactive cells. The
cases were classified positive when VEGFR1 immunoreac-
tivity was > 2% of tumor cells examined. For TWIST1 ana-
lysis, the sections were incubated with a mouse
monoclonal antibody (Twist2C1a, 1:50 dilution; Abcam,
Cambridge, United Kingdom) and only cells with > 3% of
stained epithelial nuclei were regarded as positive, accord-
ing to median value.
All immunohistochemically stained samples were
scored in a blind manner by two independent observers.
Protein expression was quantified by counting the posi-
tive cells in 3 representative areas for each section, and
expressed as percentage of positive cells/section.
Whether a section was uninformative, either lost or con-
tained no tumor tissue, a case was judged as ‘not evalu-
able’ in the statistical analysis.
Immunohistofluorescence
Immunofluorescent analysis was performed as described
previously [17,31]. Briefly, formalin-fixed and paraffin
embedded tissue serial sections of 3 μm in thickness were
deparaffinized with xylene, and rehydrated in an ethanol
series. Antigen retrieval was carried out immersing slides
in a 0.01 M saline citrated buffer (pH 6.0) at 95°C for 40
min, then tissues were permeabilized with 0.1% Triton
X100-Phosphate Buffered Saline for 15 minutes, blocked
30 min with 1% Bovine Serum Albumin-Phosphate Buf-
fered Saline and incubated overnight at 4°C in a humidi-
fied chamber or with mouse monoclonal antibody anti-
NHERF1 (6/EBP50, 1:20 dilution; BD Transduction
Laboratories, Franklin Lakes, NJ, USA) together with a
rabbit polyclonal antibody anti-VEGFR1 (C-17, 1:40 dilu-
tion; Santa Cruz Biotechnology Inc.) or with a mouse
monoclonal anti-CD31 (NCL-CD31-1A10, 1:50 dilution;
Novocastra Laboratories Ltd.) together with a rabbit poly-
clonal anti-NHERF1 (PA1-090, 1 μg/100 μL dilution; Affi-
nity Bio-Reagents). The slides were then incubated at
room temperature for 1 h with the Alexa Fluor 488 and
Alexa Fluor 568 immunoglobulin G secondary conjugated
antibodies (1:2000 dilution; Molecular Probes Inc., Eugene,
OR, USA) and mounted with DAPI (ProLong
® Gold anti-
fade reagent; Molecular Probes Inc.). Positive control
slides that were run simultaneously were used for asses-
sing the quality of immunoreactivity. For negative con-
trols, slide sections that were immunopositive were treated
with 1% Bovine Serum Albumin instead of the primary
antibody, and no reactivity was observed in any of these
controls. Images were obtained on a BX40 microscope
(Olympus, Tokyo, Japan) with a SenSys 1401E-Photo-
metrics charge-coupled device camera. To verify protein
colocalization, each acquired stack was merged by trans-
forming the three channels corresponding to red (tetra-
methylrhodamine B isothiocyanate), green (fluorescein
isothiocyanate) and blue (4’,6-diamidino-2-phenylindole)
into a single three-color stack by using the “RGB merge”
command of ImageJ software (National Institutes of
Health Bethesda, MD).
Statistical analysis
Analysis of tumor marker expressions and various clini-
copathological features was determined by the Fisher’s
exact, Pearson c
2 or c
2 test as appropriate. Correlation
between two continuous variables was assessed by the
Pearson’s rank test. A multivariate logistic regression
model was used for multivariate analysis, computing
odds ratio (OR) and 95% confidence intervals (95% CI).
All tests were two-sided with a 95% CI, and a p value
less than 0.05 was considered statistically significant.
Data analysis was carried out using the statistical pack-
age SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Relationship between tumor markers and
clinicopathological features
A summary of the tumor marker expressions categorized
according to the median values is provided in Table 1.
Overexpression of cytoplasmic and membranous
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31%, 13%, 50%, 37% and 51% of tumors, respectively.
The significant associations between tumor markers and
clinicopathological features are summarized in Table 2.
All breast cancers showed NHERF1 protein localized in
the cytoplasm of tumor cells and 31% of overexpressing
cytoplasmic NHERF1 tumors exhibited a significant asso-
ciation with tumor grade 3 (p = 0.035), negative PR status
(p = 0.008), high MIB1 (p = 0.033), positive HER2 status
(p = 0.036) and with moderate NPI (p = 0.029). In 13% of
tumors, in addition to cytoplasmic NHERF1 immunoreac-
tivity, NHERF1 showed also a plasma membrane localiza-
tion; these overexpressing membranous NHERF1 tumors
(13%) were significantly associated with tumor grade 2
(p = 0.037), positive PR status (p = 0.031), low MIB1 (p =
0.029) and with good NPI (p = 0.016). HIF-1a expression
showed a significant association with tumor grade 2 (p =
0.001), negative PR status (p = 0.013), high MIB1 (p =
0.020) and moderate NPI (p = 0.029). VEGFR1 expression
showed a significant association with negative PR status
(p = 0.006). Expression of TWIST1 was statistically preva-
lent in low MIB1 tumors (p = 0.040). There was no statis-
tically significant association between NHERF1, VEGFR1,
HIF-1a, TWIST1 expressions and age, tumor size, PVI,
nodal and ER status. Of 46 tumors with positive cytoplas-
mic NHERF1 expression, 31 (67%) exhibited positive
VEGFR1 expression. While, of 104 cases with negative
cytoplasmic NHERF1, 54 (52%) exhibited negative
VEGFR1 expression. Pearson’s rank test showed that cyto-
plasmic NHERF1 expression was positively correlated to
VEGFR1 (r = 0.382, p = 0.000) (Figure 1A). The analysis
of their relative localization by immunohistofluorescence
studies indicated that the receptor VEGFR1 colocalized
with NHERF1 when both proteins were overexpressed
within cytoplasmic and/or membranous compartments in
invasive clusters disseminated into the stroma (Figure 1B).
Tumors positive for both cytoplasmic NHERF1 and
VEGFR1 expressions, compared to those with negative
expressions, resulted significantly associated with tumor
grade 3 (p = 0.006), negative ER (p = 0.045) and PR status
(p = 0.000) (data not shown). Furthermore, correlation
analysis revealed that cytoplasmic NHERF1 expression
levels were positively correlated with increasing ER levels
(p = 0.022) (data not shown).
Out of 187 cancers, 87 (46%) were grade 2 (Table 1)
and these statistically inversely correlated with the PVI
Table 2 Association between tumor markers expression and clinicopathological features
Parameter Cytoplasmic NHERF1 Membranous NHERF1 HIF-1a VEGFR1 TWIST1
Positive Positive Positive Positive Positive
Tumor grade
1 6 (21) 7 (25) 13 (48) 12 (44) 15 (58)
2 17 (24) 14 (19) 33 (49) 34 (46) 35 (57)
3 23 (43) 3 (6) 12 (20) 36 (57) 23 (43)
p value
1 0.035 0.037 0.001 NS NS
PR status
Negative 27 (43) 4 (6) 29 (44) 43 (63) 29 (45)
Positive 19 (22) 16 (18) 18 (24) 37 (40) 42 (56)
p value
2 0.008 0.031 0.013 0.006 NS
MIB1
Negative 14 (22) 13 (21) 20 (28) 30 (44) 38 (61)
Positive 34 (40) 7 (8) 37 (46) 50 (54) 33 (43)
p value
2 0.033 0.029 0.020 NS 0.040
HER2 status
Negative 34 (29) 15 (12) 46 (37) 67 (53) 55 (49)
Positive 11 (55) 2 (11) 8 (40) 11 (55) 14 (70)
p value
2 0.036 NS NS NS NS
NPI
Good 5 (13) 10 (26) 10 (24) 18 (45) 21 (58)
Moderate 24 (32) 8 (11) 28 (37) 40 (50) 33 (49)
Poor 15 (38) 2 (5) 20 (53) 24 (55) 19 (49)
p value
1 0.029 0.016 0.029 NS NS
Data presented as number of tumors and (%)
Abbreviations: Tumor grade = histological differentiation grade; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; NPI =
Nottingham Prognostic Index.
1 p values were calculated with the use of the c
2 test;
2 p values were calculated with the use of the Fisher’s exact test
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0.012) and MIB1 (p = 0.000), and directly correlated with
ER (p = 0.000) and PR (p = 0.025) status.
Prognosis analysis
When we applied the NPI to 187 breast patients, 49
(26%) were in the good prognostic group, 88 (47%) in the
moderate prognostic group and 50 (27%) in the poor
prognostic group (Table 1). We examined if tumors with
grade 2 and poor prognosis were associated with some
distinct clinicopathological parameters or with some
tumor markers not currently used in routine diagnosis.
Subgroup analysis revealed that the PVI (p = 0.023) and
negative membranous NHERF1 expression (p = 0.028)
were adverse prognostic factors for grade 2 tumors
(Figure 2A, 3). When we analyzed the distribution of the
PVI/membranous NHERF1 immunophenotypes in the
three distinct histological groups, we showed that 72% of
grade 2 and 92% of grade 3 tumors were significantly
associated to the PVI+/membranous NHERF1-expression
phenotype, both characterized by a poor prognosis (p =
0.000) (Figure 2B). Then, we explored the prognostic
Figure 1 Analysis of cytoplasmic NHERF1 and VEGFR1 expressions in invasive breast cancer. (A) The correlation between protein
expression of cytoplasmic NHERF1 and VEGFR1 was evaluated by Pearson’s rank correlation coefficient analysis, and a positive significant
correlation was established. (B) A representative tissue sample stained with NHERF1 and VEGFR1 antibodies and detected with Alexa Fluor 568
(red) and Alexa Fluor 488 (green) secondary antibodies, respectively, prior to fluorescence microscopy analysis. Arrowheads indicate invasive cells
disseminated into the stroma with a high global expression of two proteins, where NHERF1 co-localized with VEGFR1 on cytoplasmic and
membranous compartments. Scale bar = 10 μm.
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notypes in the whole cohort and, notably, 100% of
tumors with poor prognosis significantly displayed the
PVI+/membranous NHERF1- expression phenotype,
compared with 27% of tumors with good prognosis (p =
0.000) (Figure 2C). Moreover, the PVI+/membranous
NHERF1-phenotype in the subgroup of grade 2 familial
tumors showed a higher significant proportion than pro-
portion within subgroup of grade 2 sporadic tumors (90%
vs. 50%; p = 0.030) (Figure 2D).
Univariate and binary logistic regression analyses on 187
cancers were performed to evaluate the associations
between tumor markers and NPI. The tumor size, PVI, ER
status, expression of MIB1 and HIF-1a were all significant
factors strongly associated with worse prognosis (p =
0.031, p = 0.000, p = 0.000, p = 0.001 and p = 0.011,
respectively). Interestingly, only the presence of membra-
nous NHERF1 resulted a favorable prognostic factor (p =
0.012) (data not shown). Subsequently, when we have eval-
uated the prognostic relevance of the significant univariate
parameters, a multivariate logistic regression analysis
revealed poor prognosis correlated with the PVI and MIB1
(p = 0.000 and p = 0.001, respectively) (Table 3).
Discussion
Clinical and pathological factors, such as nodal status,
tumor grade, proliferative activity, receptor status and
HER2 overexpression, are currently used for determining
the risk of relapse of breast cancer patients. Traditional
prognostic factors have shown limited ability to predict
distinct patient outcomes and individuals with the same
clinical assessment can have markedly different courses
[32]. Prognostic heterogeneity is complicated by a myriad
of liable alterations within multiple biological pathways,
stressing the need for further studies on molecular events
involved in cancerogenesis,t u m o rp r o g r e s s i o na n d
metastasis.
In this study, we explored traditional prognostic factors
and a panel of tumor markers not used in routine diagno-
sis, such as NHERF1, VEGFR1, HIF-1a and TWIST1, that
have been respectively related to breast cancer progression
[17-19], aggressiveness [21,22], hypoxic response [29,33]
and cell invasion/metastasis [24,34], assessing if they are
differentially expressed in tumors scored as grade 2, in
order to best characterize them. We showed that several
parameters discriminated poor versus good clinical out-
come on 187 patients, but the PVI together with MIB1
were the two variables that remained strongly associated
with worse prognosis in multivariate analysis. Our results
are consistent with numerous findings, which highlight
proliferation-related genes as the main and common
denominator for predicting clinical outcome [35,36]. How-
ever, it is not surprising that these genes are involved in
breast cancer prognosis, considering that the increased
Figure 2 Prognostic relevance of peritumoral vascular invasion
and membranous NHERF1 in invasive breast cancer. (A)
Subgroup analysis revealed that the presence of PVI and the loss of
membranous NHERF1 expression were adverse prognostic factors
for grade 2 tumors (by Fisher’s exact test). (B) The distribution
analysis in the three distinct histological groups showed the PVI
+/membranous NHERF1- expression phenotype significantly
associated both to grade 2 and to grade 3 tumors (by c
2 test). (C)
The PVI+/membranous NHERF1- expression immunophenotype
predicted poor prognosis in the whole cohort (by Fisher’s exact
test). (D) The PVI+/membranous NHERF1- expression
immunophenotype correlated significantly with poor clinical
outcome also in the subgroup of grade 2 familial tumors (by
Fisher’s exact test). Abbreviations: NPI = Nottingham Prognostic
Index; PVI = peritumoral vascular invasion; neg = negative; pos =
positive.
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Page 7 of 11Figure 3 Peritumoral vascular invasion and NHERF1 expression in grade 2 invasive breast carcinoma. (A) Representative images of
peritumoral vascular invasion by H&E and NHERF1 protein expression by immunoistochemistry: (I) a tumor with the absence of peritumoral
vascular invasion and (II) with the overexpression of membranous NHERF1, in addition to cytoplasmic localization (arrow). (III) A case showing
peritumoral vascular invasion (arrowhead) and (IV) negative expression of membranous NHERF1. Original magnification × 100, inset × 200. (B)
Assessment of the peritumoral vascular invasion in a breast tumor section stained with CD31 and NHERF1 antibodies and detected with Alexa
Fluor 568 (red) and Alexa Fluor 488 (green) secondary antibodies, respectively. Immunofluorescence analysyis shows a tumor cell cluster within
the endothelial-lined vascular space (arrowheads), with strong cytoplasmic NHERF1 expression similarly to the invasive cellular component at
right zone of the image. Scale bar = 10 μm.
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two of the features common to breast carcinomas.
In the present study, overexpression of cytoplasmic
NHERF1 resulted associated with unfavorable prognosis
and aggressive clinical parameters, as previously demon-
strated [18,31]. However, in line with several reports
describing the NHERF1 gene as transcriptionally regu-
lated by estrogen [18,31,37], here we demonstrated that
cytoplasmic NHERF1 expression was significantly corre-
lated with increasing ER expression. Interestingly, we
also observed a significant direct correlation between
increased levels of cytoplasmic NHERF1 and VEGFR1.
Tumors overexpressing NHERF1 and VEGFR1 revealed
an association with poor outcome, being characterized
by an increasing tumor grade, and negative status of
steroid hormone receptors. It is now clear that NHERF1
promotes dimerization and activation of many tyrosine
kinase receptors, such as the platelet derived growth fac-
tor receptor [38], the epidermal growth factor receptor
[39] and the HER2 [17], known to directly regulate cell
pathways related to cancer progression. Previously, we
observed that VEGFR1 was expressed in the cytoplasm
of breast cancer cells, where also NHERF1 expression
w a sp r e d o m i n a n t[ 1 9 ] .I nt h i sc o n t e x t ,N H E R F 1a c t sa s
a potential interacting partner of VEGFR1, a marker
correlated with high metastasis risk and relapse [21,22],
probably promoting invasion of tumor cells through
autocrine and paracrine mechanisms [40].
In our series, tumors of grade 2 represent 46% of the
whole cohort, confirming previous observations that this
constitutes a substantial proportion of cases in current
routine breast cancer diagnostics [41]. The Elston and Ellis
modified grading system provides a simple, inexpensive
and routinely applicable overview of the intrinsic biological
characteristics and clinical behavior of tumors [4]. Grade 2
tumors usually show an intermediate outcome during the
early years of follow-up, leading to speculate the uncertain
role of histological grade in therapeutic planning due to
the not informative results for clinical decision making [6].
Further sub-classification of grade 2 tumors, possibly into
low and high risk categories, would be beneficial to
improve prognostic stratification of these patients. Nota-
bly, we found that grade 2 tumors exhibited significant
correlation with parameters of low-risk significance, such
as small tumor size, lower nodal stage and proliferative
activity and positive steroid hormone receptor status.
Afterwards, we investigated what traditional clinicopatho-
logical parameters and new potential markers, such as
NHERF1, VEGFR1, HIF-1a and TWIST1, could best char-
acterize grade 2 tumors with poor prognosis. Our results
demonstrated that a distinct immunophenotype, PVI/
membranous NHERF1, is able to categorize grade 2
tumors into two defined subgroups, which exhibited sig-
nificantly different prognosis. Interestingly, 72% of grade 2
tumors with the PVI+/membranous NHERF1- expression
phenotype were associated to an adverse prognosis. How-
ever, a significant high proportion of grade 3 tumors
showed the same PVI+/membranous NHERF1- expression
phenotype, highlighting that grade 2 tumor subgroup with
poor prognosis is regarded as being similar to grade 3 can-
cers. Relevantly, also in the whole cohort the PVI+/mem-
branous NHERF1- expression phenotype displayed a
significant correlation with poor prognosis tumors. Since,
according to these results, the PVI+/membranous
NHERF1- expression phenotype in grade 2 tumors is a
poor prognosis factor, we have analyzed PVI/membranous
NHERF1 immunophenotypes in a subgroup of patients
stratified as having a family history of breast cancer, a
category with high biological malignancy, as previously
notified [1,19]. Intriguingly, it was emerged that familial
tumors with grade 2 were prevalently associated to the
PVI+/membranous NHERF1-expression subset, confirm-
ing one more time the prognostic relevance of this tumor
immunophenotype.
The pathological significance of the PVI, a marker of
tumor with metastatic potential and a predictor of breast
cancer outcome, has long been appreciated. In the 9th St
Gallen meeting, the presence of vascular invasion was
included in the category of relevant prognostic factors in
lymph node-negative patients [42]. Efforts to detect early
metastatic activity, such as diligent pathological examina-
tion of sentinel lymph node biopsies would be compli-
mented by the objective evaluation of vascular invasion
status of the primary tumor [43]. Vascular invasion has
been recently reported as a histoclinical parameter inde-
pendently associated with poorer survival inside both
Table 3 Multivariate logistic regression analysis for
tumor markers predicting prognosis of 187 invasive
breast cancer patients
Variable Odds ratio 95% CI p value
PVI 8.656 6.186 - 9.862 0.000
Negative vs
Positive
ER status 0.007 0.000 - 0.013 0.130
Negative vs
Positive
MIB1 6.130 4.160 - 6.995 0.001
Negative vs
Positive
Membranous NHERF1 1.185 0.624 - 1.830 0.154
Negative vs
Positive
HIF-1a 1.392 0.458 - 1.865 0.178
Negative vs
Positive
Abbreviations: PVI = peritumoral vascular invasion; ER = estrogen receptor
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[44,45]. However, in a our previous work, it has been
demonstrated the predictive significance of the PVI for
familial patients with BRCA gene mutation risk [27].
Thus, on the basis of our results, the PVI assessment
might provide additional information on disease evolu-
tion of grade 2 tumors.
The adaptor protein NHERF1 shows a physiological
localization at the plasma membrane, but during breast
cancerogenesis progressively loses its apical localization
becoming mostly cytoplasmic in no longer polarized
tumor cells [17]. In our series, 13% of tumors showed
NHERF1 still localized in the plasma membrane, and were
positively associated with favorable prognosis parameters,
such as low tumor grade, positive PR status, and low pro-
liferative activity. The positive prognostic impact of mem-
branous NHERF1 is in agreement with results obtained
from our [17,18] and other laboratories [46], suggesting
that NHERF1 might behave either as a tumor suppressor,
when it is localized at the plasma membrane, or as an
oncogenic protein, when it is shifted to the cytoplasm,
depending on its subcellular distribution.
Moreover, in the present study the good prognostic
relevance of membranous NHERF1 has been demon-
strated both in the whole cohort and in subgroup of
grade 2 tumors. From a clinical perspective, the PVI
+/membranous NHERF1- expression phenotype could
improve the accuracy of predicting clinical outcome for
a subgroup of patients. Therefore, the current results
indicate that the combination of those two markers may
be applicable as predictive markers to select patients for
more aggressive treatment and follow-up.
Conclusions
We showed in this study that cytoplasmic NHERF1
colocalizes with the oncogenic receptor VEGFR1 and
their significant correlation suggests new potential
implications in breast tumor progression. The PVI
results the major variable strongly associated with poor
prognosis both in the whole series of invasive cancers
and in the grade 2 tumors, improving ability to accu-
rately predict risk of progre s s i o n .F u r t h e r ,i th a sb e e n
demonstrated the intrinsic biological differences charac-
terizing grade 2 tumors, which represent a combination
of two histological subtypes with low or high clinical
relevance. In particular, the PVI+/membranous
NHERF1- expression immunophenotype identifies a
category of grade 2 tumors with the worst prognosis,
including patients with a family history of breast cancer.
These observations support the idea of the PVI+/mem-
branous NHERF1- expression phenotype as a useful
marker for the identification of a subset of grade 2
tumors with clinical high risk of poorer prognosis.
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